Skip to main content

Commercial E-Prescribing Cuts Medication Errors in Hospitals

February 1, 2012 — Implementation of 2 commercial e-prescribing systems significantly reduced prescribing errors, including serious errors, at 2 Australian hospitals, according to results from a study published online January 31 in PloS Medicine.
"Considerable investments are being made in commercial electronic prescribing systems (e-prescribing) in many countries," write lead author Professor Johanna Westbrook, PhD, from the University of New South Wales, Sydney, Australia, and colleagues.
However, they note, "Few studies have measured or evaluated their effectiveness at reducing prescribing error rates, and interactions between system design and errors are not well understood, despite increasing concerns regarding new errors associated with system use."
These researchers evaluated the effect of 2 commercially available e-prescribing systems on reducing prescribing errors and assessed their propensity for creating new types of errors.
The authors looked for procedural and clinical errors in medication charts at 2 Sydney teaching hospitals, both before and after the introduction of e-prescribing systems. Procedural errors included unclear, incomplete, or illegal prescribing orders, and clinical errors included prescribing an incorrect drug or incorrect dose.
At hospital A, the Cerner Millennium e-prescribing system was introduced on a single geriatric ward. Three other wards (a renal/vascular ward, a respiratory ward, and another geriatric ward) served as controls.
At hospital B, the researchers compared error rates in 2 wards (psychiatry and cardiology) both before and after the iSoft MedChart system was introduced.
"The introduction of an e-prescribing system was associated with a substantial reduction in error rates in the three intervention wards; error rates on the control wards did not change significantly during the study," the researchers write.
In hospital A, error rates declined from 6.25 (95% confidence interval [CI], 5.23 - 7.28) to 2.12 (95% CI, 1.71 - 2.54; P < .0001) per admission after the e-prescribing system was put into use, the researchers say.
Similar results were seen in hospital B, with error rates falling from 3.62 (95% CI, 3.30 - 3.93) to 1.46 (95% CI, 1.20 - 1.73; P < .0001) per admission.
The researchers attributed the decline in error rates primarily to reductions in procedural errors; clinical errors showed only modest reductions.
However, the authors stress that the introduction of e-prescribing had a significant effect on serious errors, defined as errors that would be likely to lead to death. Rates for serious errors fell across all the intervention wards, from 0.25 per admission to 0.14 per admission (P = .0002), which is a 44% decline.
In contrast, serious error rates in control wards declined by only 17% during the study.
System-related errors (eg, choosing an incorrect drug from a drop-down menu) were responsible for about 35% of the errors seen in the intervention wards after the e-prescribing systems were put into place, the authors write.
That high rate of system-related errors is worrisome, the authors concede, but they say such errors could be corrected by tweaking the systems and improving user training.
The authors point out several limitations of the study, including lack of control wards in hospital B and the inability to randomize hospital wards to the intervention.
Commenting on the study, Lyman Dennis, MBA, PhD, who heads El Dorado Health Consulting in Fairfield, California, told Medscape Medical News, "This study is important because it verifies that electronic systems do improve care, both in terms of improving the accuracy of procedural steps as well as clinical execution. But it also clearly shows that the factor of human error is not removed simply by utilizing these information systems."
Dr. Dennis says another point highlighted by the findings is that hospitals need to have implementation of e-prescribing systems imbedded in some sort of quality improvement process. "You shouldn't have the expectation that when you've finished implementing the system everything is immediately going to proceed smoothly," he said.
Most e-prescribing systems offer a multitude of choices when navigating various screens, and Dr. Dennis points out that although having lots of choices creates flexibility, it can also cause errors. "When many options are offered, making the proper selection can involve a rather fine mouse click, or a fine touch of the screen, and it can be easy to make an incorrect choice," he said.
However, on balance, Dr. Dennis says, e-prescribing makes sense for hospitals. "Though, as we've seen in this study, such systems are associated with an increase in system-related errors, the reduction in serious procedural and clinical errors more than makes up for that," he said.
The research was supported by grants from the National Health and Medical Research Council. One of the study authors has, in the past, had shares and acted as a consultant to give general advice on incident reporting to Patient Safety International. He also was a board member of Patient Safety International, which at that stage was, but is no longer, a subsidiary of the not-for-profit research organization the Australian Patient Safety Foundation, of which he has been and is president. Another coauthor spoke on "Electronic Medication Management and the Hospital Pharmacist" at the Cerner Regional User Group meeting in 2010 at the request of her employer. She personally received no honorarium or fees from this speaking engagement. The other authors and Dr. Dennis have disclosed no relevant financial relationships.
PloS Med. Published online January 31, 2012. Article

Comments

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volum...

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n...